Research programme: B-RAF kinase inhibitors - Aravive BiologicsAlternative Names: B-series
Latest Information Update: 06 Dec 2016
At a glance
- Originator Ruga Corporation; Selexagen Therapeutics
- Developer Aravive Biologics
- Mechanism of Action Mitogen-activated protein kinase inhibitors; Proto oncogene protein b raf inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer